Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00010)
| Name |
Myelodysplastic syndrome
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2A3Z
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Myelodysplastic syndrome [ICD-11: 2A3Z] | ||||
| Responsed Drug | Decitabine | Investigative | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Necroptosis | hsa04217 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell necroptosis | |||||
| In Vitro Model | SKM-1 cells | Acute myeloid leukemia | Homo sapiens | CVCL_0098 | |
| MUTZ-1 cells | Burkitt lymphoma | Homo sapiens | CVCL_1431 | ||
| In Vivo Model |
C57BL/6 mice were purchased from Vital River (Beijing, China) at 6 to 8 weeks of age. Twenty mice were housed with five individuals per cage and used at a weight of approximately 20.0-22.0 g. They were randomly divided into four groups, five in each group, namely control group, low-dose group, middle-dose group, and high-dose group. The low-, middle-, and high-dose group mice were administered an intraperitoneal injection of 0.2-ml iron dextran at a concentration of 6.25, 12.5, and 25 mg/ml, respectively, every 3 days for 10 weeks to establish iron overload model. At the same time, normal saline was given to the control group.
Click to Show/Hide
|
||||
| Response regulation | Ferroptosis may account for the main mechanisms of how decitabine induced death of myelodysplastic syndrome (MDS) cells. Decitabine-induced ROS raise leads to ferroptosis in MDS cells by decreasing GSH level and GPX4 activity. | ||||